Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03865706 · ClinicalTrials.gov registry record · Phase 2
Inulin for Infections in the Intensive Care Unit
A Phase 2 study of Critical Illness and Sepsis, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT03865706 is a Phase 2 study of Critical Illness and Sepsis that has completed, run by Columbia University. The registered enrollment target is 94 participants, below the 3,137-participant average among 91 other Critical Illness trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03865706, a Phase 2 study of Critical Illness and Sepsis, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
Normal gut bacteria prevent colonization and subsequent infection with MDR organisms (MDROs) through competition for resources and other mechanisms. During critical illness, this function of the microbiome is lost and there are no current treatments to restore it. Preliminary data indicates that the prebiotic fiber inulin is safe and may alter the gastrointestinal microbiome to improve gut barrier function, decrease colonization with MDROs, and reduce downstream risk for intensive care unit (ICU)-acquired MDR infections. However, the impact of inulin during critical illness is unknown. This double-blind, randomized clinical trial will test inulin for the prevention of antibiotic resistant infections in the ICU. The trial's specific aims are to determine (1) the feasibility, tolerability, and safety of inulin in the intensive care unit; (2) the impact of inulin on gut colonization with antibiotic-resistant pathogens; and (2A/exploratory) the impact of inulin on ICU-acquired antibiotic-resistant infections.
Conditions Studied
Interventions
- DRUG Inulin Oral Suspension
- DRUG Placebo Oral Suspension
- DRUG Broad-spectrum antibiotics
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2024-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03865706
The ClinicalTrials.gov registry entry for NCT03865706 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,137-participant average among 91 other Critical Illness trials with a reported enrollment target (97% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Critical Illness appearing as the primary indexed condition, and to 3 interventions - of which Inulin Oral Suspension is the first listed.
NCT03865706 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03865706 about?
NCT03865706 is a clinical study titled "Inulin for Infections in the Intensive Care Unit". Normal gut bacteria prevent colonization and subsequent infection with MDR organisms (MDROs) through competition for resources and other mechanisms. During critical illness, this function of the microbiome is lost and there are no current treatments to restore it. Preliminary data indicates that the...
What is the current status of trial NCT03865706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2019-10-14. Estimated completion is 2024-07-23.
What conditions does trial NCT03865706 study?
This clinical trial studies the following conditions: Critical Illness, Sepsis, Nutrition Disorders, Antibiotic Resistant Infection, Nosocomial Infection.
What interventions are being tested in trial NCT03865706?
The interventions under investigation include: Inulin Oral Suspension (DRUG), Placebo Oral Suspension (DRUG), Broad-spectrum antibiotics (DRUG).
Who is sponsoring clinical trial NCT03865706?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03865706 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Critical Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The "What Is Important to Us" Communication Intervention Pilot Clinical Trial
RECRUITING · Phase 2
-
Azithromycin for Critical Asthma - Pediatrics
RECRUITING · Phase 2
-
Practical Anemia Bundle for SusTained Blood Recovery
COMPLETED · Phase 2
-
Hypovitaminosis D in Neurocritical Patients
COMPLETED · Phase 2
-
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
RECRUITING · NA
-
Assessment of Stroke Volume in Shock Using Echocardiography Versus Bioreactive Impedance
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.